Bayer AG (BAYRY)
13.76
-0.37
(-2.62%)
USD |
OTCM |
Sep 18, 16:00
Bayer Enterprise Value : 93.25B for Sept. 18, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 18, 2026 | 93.25B |
| September 17, 2026 | 94.70B |
| September 16, 2026 | 94.39B |
| September 15, 2026 | 94.33B |
| September 14, 2026 | 95.25B |
| September 11, 2026 | 94.00B |
| September 10, 2026 | 94.47B |
| September 09, 2026 | 95.41B |
| September 08, 2026 | 95.45B |
| September 04, 2026 | 94.94B |
| September 03, 2026 | 95.55B |
| September 02, 2026 | 95.06B |
| September 01, 2026 | 94.66B |
| August 31, 2026 | 95.17B |
| August 28, 2026 | 94.27B |
| August 27, 2026 | 94.62B |
| August 26, 2026 | 95.17B |
| August 25, 2026 | 95.53B |
| August 24, 2026 | 94.66B |
| August 21, 2026 | 94.43B |
| August 20, 2026 | 94.66B |
| August 19, 2026 | 95.65B |
| August 18, 2026 | 94.64B |
| August 17, 2026 | 93.56B |
| August 14, 2026 | 93.56B |
| Date | Value |
|---|---|
| August 13, 2026 | 93.56B |
| August 12, 2026 | 93.84B |
| August 11, 2026 | 95.25B |
| August 10, 2026 | 94.98B |
| August 07, 2026 | 95.92B |
| August 06, 2026 | 95.45B |
| August 05, 2026 | 95.14B |
| August 04, 2026 | 94.11B |
| August 03, 2026 | 92.50B |
| July 31, 2026 | 93.76B |
| July 30, 2026 | 94.07B |
| July 29, 2026 | 92.78B |
| July 28, 2026 | 92.19B |
| July 27, 2026 | 91.79B |
| July 24, 2026 | 90.77B |
| July 23, 2026 | 90.77B |
| July 22, 2026 | 91.60B |
| July 21, 2026 | 92.62B |
| July 20, 2026 | 91.95B |
| July 17, 2026 | 93.41B |
| July 16, 2026 | 92.62B |
| July 15, 2026 | 92.74B |
| July 14, 2026 | 94.07B |
| July 13, 2026 | 94.82B |
| July 10, 2026 | 95.29B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Merck KGaA | 31.19B |
| Breakthrough Chemistry, Inc. | 0.0542M |
| Cardiac Biotech Solutions, Inc. | 6.729M |
| Fresenius SE & Co. KGaA | 42.24B |
| Carl Zeiss Meditec AG | 3.035B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 266.26M |
| Revenue (Quarterly) | 12.64B |
| Total Expenses (Quarterly) | 12.39B |
| EPS Diluted (Quarterly) | 0.0648 |
| Gross Profit Margin (Quarterly) | 58.24% |
| Profit Margin (Quarterly) | 2.11% |
| Earnings Yield | -3.72% |
| Operating Earnings Yield | 13.52% |
| Normalized Earnings Yield | 3.589 |